Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis.

Rheumatol Ther

Division of Rheumatology, Nemours Children's Health, 1600 Rockland Rd, Wilmington, DE, 19803, USA.

Published: February 2024

AI Article Synopsis

  • Fibroblast-like synoviocytes (FLS) are essential in inflammation related to juvenile idiopathic arthritis (JIA), with TNFα and TGFβ playing key roles in disease progression.
  • The study involved isolating FLS from synovial fluid of 41 patients, comparing the effects of adalimumab treatment against untreated cells.
  • Results showed that after 24 hours, adalimumab significantly influenced protein levels, indicating its potential effectiveness in reducing inflammation associated with JIA.

Article Abstract

Introduction: Fibroblast-like synoviocytes (FLS) play a critical role in inflammation that contributes to disease progression in juvenile idiopathic arthritis (JIA). In rheumatoid arthritis (RA), FLS express tumor necrosis factor alpha (TNFα). TNFα signaling has been shown to be upstream of transforming growth factor beta (TGFβ) signaling. Overexpression of TNFα and TGFβ, as well as related proteins, can cause increased inflammation in RA. In this study, we examine the effects of inhibiting TNFα signaling with adalimumab on FLS isolated from synovial fluid of patients with JIA.

Methods: Synovial fluid samples were selected from 41 patients in our repository. Of these samples, 23 were diagnosed with persistent oligoarticular JIA and 18 were diagnosed with extended oligoarticular JIA. All samples were taken prior to patients extending to a polyarticular course, or what we termed extended-to-be (ETB), and were on no medications or nonsteroidal anti-inflammatory drugs (NSAIDs) only at the time of arthrocentesis. For cell studies, FLS were isolated from synovial fluid and treated with adalimumab for 24 h. Protein antibody arrays were performed by RayBiotech, Inc. according to their protocols.

Results: In persistent FLS, TNFα (fold change [FC] = 1.2 p = 0.001), TGFβ (FC = 1.5 p = 0.001), lymphotoxin alpha (LTα) (FC = 4.3 p = 0.015), soluble tumor necrosis factor receptor 1 (sTNFRI) (FC = 5.1 p = 0.008), and soluble tumor necrosis factor receptor 2 (sTNFRII) (FC = 3.8 p = 0.025) were significantly elevated in adalimumab treated cells compared to untreated cells. In ETB FLS, TNFα was significantly elevated (FC = 1.04 p = 0.023) while TGFβ (FC = 1.03 p = 0.037) was significantly decreased in adalimumab-treated cells compared to untreated cells.

Conclusions: This data suggests that, after only 24 h, adalimumab is effective at decreasing inflammation that occurs downstream of initial TNFα signaling in extended-to-be fibroblast-like synoviocytes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10796900PMC
http://dx.doi.org/10.1007/s40744-023-00628-zDOI Listing

Publication Analysis

Top Keywords

tnfα signaling
16
tumor necrosis
12
necrosis factor
12
synovial fluid
12
tnfα
8
extended oligoarticular
8
juvenile idiopathic
8
idiopathic arthritis
8
fibroblast-like synoviocytes
8
fls isolated
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!